{"transactions":[{"id":806934,"issuer":{"id":7122,"kind":"organization","name":"Xilio Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-16T21:12:22.000Z","date":"2026-04-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 15, 2026 and will vest in three equal installments on April 15, 2027, April 15, 2028 and April 15, 2029, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":8.4,"expiration_date":"2036-04-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-159316","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000119312526159316/ownership.xml","form_type":"4"}},{"id":839777,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":false,"shares":25131,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On March 15, 2024, the Reporting Person was granted 75,395 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"On March 15, 2024, the Reporting Person was granted 75,395 RSUs vesting in three equal annual installments beginning on March 15, 2025. This transaction reflects the second vesting installment of such RSU award."}],"balance_after":25132,"derivative":{"underlying":"Common Stock","underlying_shares":25131},"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":839776,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":false,"shares":24519,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On March 14, 2025, the Reporting Person was granted 73,559 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"On March 14, 2025, the Reporting Person was granted 73,559 RSUs vesting in three equal annual installments beginning on March 14, 2026. This transaction reflects the first vesting installment of such RSU award."}],"balance_after":49040,"derivative":{"underlying":"Common Stock","underlying_shares":24519},"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":839775,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":12104,"price":14.2,"value":171876.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Reflects an aggregate of 12,104 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2026."}],"balance_after":258788,"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":839774,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-15","kind":"exercise","planned":false,"acquired":true,"shares":25131,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Issuer common stock."}],"balance_after":270892,"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":839773,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":14728,"price":14.2,"value":209137.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects an aggregate of 14,728 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs and PSUs that vested on March 14, 2026."}],"balance_after":245761,"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":839772,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-14","kind":"grant","planned":false,"acquired":true,"shares":24520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On March 14, 2025, the Reporting Person was granted 73,559 performance-based phantom RSUs (\"PSUs\") with vesting contingent upon the achievement of pre-established performance and strategic targets. This transaction represents the first vesting installment of such PSU award."}],"balance_after":260489,"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":839771,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-17T23:42:01.000Z","date":"2026-03-14","kind":"exercise","planned":false,"acquired":true,"shares":24519,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Issuer common stock."}],"balance_after":235969,"source":{"system":"sec-edgar","filing":"0001193125-26-111494","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526111494/ownership.xml","form_type":"4"}},{"id":849589,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-03-11T20:24:57.000Z","date":"2026-03-09","kind":"exercise","planned":false,"acquired":false,"shares":20001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 9, 2023, the Reporting Person was granted 60,004 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 9, 2023, the Reporting Person was granted 60,004 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20001},"source":{"system":"sec-edgar","filing":"0001193125-26-102239","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526102239/ownership.xml","form_type":"4"}},{"id":849588,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T20:24:57.000Z","date":"2026-03-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":5871,"price":14.96,"value":87830.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 5,871 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026."}],"balance_after":211450,"source":{"system":"sec-edgar","filing":"0001193125-26-102239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526102239/ownership.xml","form_type":"4"}},{"id":849587,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T20:24:57.000Z","date":"2026-03-09","kind":"exercise","planned":false,"acquired":true,"shares":20001,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of Issuer common stock."}],"balance_after":217321,"source":{"system":"sec-edgar","filing":"0001193125-26-102239","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000119312526102239/ownership.xml","form_type":"4"}},{"id":1074369,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":6432},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074368,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12155,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":12155},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074367,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5017,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":5017},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074366,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.03,"underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074365,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.38,"underlying":"Common Stock","underlying_shares":18068},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074364,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36690,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":6.02,"underlying":"Common Stock","underlying_shares":36690},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074363,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":1.89,"underlying":"Common Stock","underlying_shares":24984},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074362,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24761,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option."}],"balance_after":0,"derivative":{"exercise_price":3.39,"underlying":"Common Stock","underlying_shares":24761},"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1074361,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-05T13:30:51.000Z","date":"2025-08-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents Restricted Stock Units (\"RSUs\"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, Sanofi (\"Parent\"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the \"Effective Time\"), Merger Sub merged with and into the Issuer (the \"Merger\"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the \"Closing Amount\") plus (ii) one contingent value right (\"CVR\"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents Restricted Stock Units (\"RSUs\"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-102476","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025102476/ownership.xml","form_type":"4"}},{"id":1135076,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-24T00:41:42.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock.  The shares shall vest upon the earlier to occur of (i) May 22, 2026 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000950170-25-077268","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017025077268/ownership.xml","form_type":"4"}},{"id":1201984,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2025-03-18T21:15:49.000Z","date":"2025-03-17","kind":"exercise","planned":false,"acquired":false,"shares":25132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025."}],"balance_after":50263,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":25132},"source":{"system":"sec-edgar","filing":"0001171843-25-001531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001531/ownership.xml","form_type":"4"}},{"id":1201983,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2025-03-18T21:15:49.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":71403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 71,403 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 71,403 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold."}],"balance_after":71403,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":71403},"source":{"system":"sec-edgar","filing":"0001171843-25-001531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001531/ownership.xml","form_type":"4"}},{"id":1201982,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2025-03-18T21:15:49.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":73559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026."}],"balance_after":73559,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":73559},"source":{"system":"sec-edgar","filing":"0001171843-25-001531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001531/ownership.xml","form_type":"4"}},{"id":1201981,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2025-03-18T21:15:49.000Z","date":"2025-03-17","kind":"tax_withholding","planned":false,"acquired":false,"shares":12152,"price":15.91,"value":193338.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 12,152 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the closing price of ANIK common stock on March 14, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":197320,"source":{"system":"sec-edgar","filing":"0001171843-25-001531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001531/ownership.xml","form_type":"4"}},{"id":1201980,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2025-03-18T21:15:49.000Z","date":"2025-03-17","kind":"exercise","planned":false,"acquired":true,"shares":25132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the first vesting installment of phantom RSUs granted on March 15, 2024, which the Company elected to settle in shares."}],"balance_after":209472,"source":{"system":"sec-edgar","filing":"0001171843-25-001531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001531/ownership.xml","form_type":"4"}},{"id":1208408,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2025-03-13T21:15:43.000Z","date":"2025-03-11","kind":"exercise","planned":false,"acquired":false,"shares":30060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30060},"source":{"system":"sec-edgar","filing":"0001171843-25-001467","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001467/ownership.xml","form_type":"4"}},{"id":1208407,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2025-03-13T21:15:43.000Z","date":"2025-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":12675,"price":16.79,"value":212813.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 12,675 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the closing price of ANIK common stock on March 11, 2025, the trading day to which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":184340,"source":{"system":"sec-edgar","filing":"0001171843-25-001467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001467/ownership.xml","form_type":"4"}},{"id":1208406,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2025-03-13T21:15:43.000Z","date":"2025-03-11","kind":"exercise","planned":false,"acquired":true,"shares":30060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the third and final vesting installment of RSUs granted on March 11, 2022."}],"balance_after":197015,"source":{"system":"sec-edgar","filing":"0001171843-25-001467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001467/ownership.xml","form_type":"4"}},{"id":1213497,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2025-03-11T21:17:13.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":false,"shares":20002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024."}],"balance_after":20001,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":20002},"source":{"system":"sec-edgar","filing":"0001171843-25-001404","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001404/ownership.xml","form_type":"4"}},{"id":1213496,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2025-03-11T21:17:13.000Z","date":"2025-03-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":5871,"price":16.62,"value":97576.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects an aggregate of 5,871 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the closing price of ANIK common stock on March 7, 2025, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":166955,"source":{"system":"sec-edgar","filing":"0001171843-25-001404","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001404/ownership.xml","form_type":"4"}},{"id":1213495,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2025-03-11T21:17:13.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":true,"shares":20002,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the second vesting installment of RSUs granted on March 9, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2024 and 330 shares purchased on November 14, 2024."}],"balance_after":172826,"source":{"system":"sec-edgar","filing":"0001171843-25-001404","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184325001404/ownership.xml","form_type":"4"}},{"id":1486556,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-06-07T21:05:02.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":18068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's 2021 Stock Option and Incentive Plan. The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 5, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":18068,"derivative":{"exercise_price":3.38,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":18068},"source":{"system":"sec-edgar","filing":"0000950170-24-070837","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024070837/ownership.xml","form_type":"4"}},{"id":1524582,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":13928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":13928,"derivative":{"exercise_price":3.03,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524581,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This stock option award was issued pursuant to the 2021 Plan and shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":0,"derivative":{"exercise_price":10,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524580,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":6432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation and the shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":6432,"derivative":{"exercise_price":3.03,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":6432},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524579,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6432,"price":7.618,"value":48998.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation and the shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":11.87,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":6432},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524578,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":12155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":12155,"derivative":{"exercise_price":3.03,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":12155},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524577,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option award was issued pursuant to the 2021 Plan and the shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":3.1,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":12155},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524576,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"grant","planned":false,"acquired":true,"shares":5017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of the stock option award is $3.03 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date.  Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the one-year anniversary of the Effective Date, (ii) a Sale Event (as defined in the 2021 Plan) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2021 Plan) by the Company other than for Cause (as defined in the 2021 Plan) or due to the Reporting Person's death or disability."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation and the shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":5017,"derivative":{"exercise_price":3.03,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":5017},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1524575,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Award (Right to Buy)","published_at":"2024-05-07T21:00:26.000Z","date":"2024-05-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5017,"price":9.63,"value":48313.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 3, 2024, pursuant to the terms of the Issuer's 2021 Stock Option and Incentive Plan (the \"2021 Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024 (the \"Effective Date\").  Except for the new exercise price (see footnote 3 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation and the shares subject to this stock option award are fully vested and exercisable as of the date hereof."}],"balance_after":0,"derivative":{"exercise_price":16.13,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":5017},"source":{"system":"sec-edgar","filing":"0000950170-24-054695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024054695/ownership.xml","form_type":"4"}},{"id":1570704,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-19T21:16:20.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":182699,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a 10% premium above the closing price of Anika's common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The premium priced stock options vest in three equal annual installments beginning on March 15, 2025."}],"balance_after":182699,"derivative":{"exercise_price":27.98,"expiration_date":"2034-03-11","underlying":"Common Stock","underlying_shares":182699},"source":{"system":"sec-edgar","filing":"0001171843-24-001458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001458/ownership.xml","form_type":"4"}},{"id":1570703,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2024-03-19T21:16:20.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":75395,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025."}],"balance_after":75395,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":75395},"source":{"system":"sec-edgar","filing":"0001171843-24-001458","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001458/ownership.xml","form_type":"4"}},{"id":1582400,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"exercise","planned":false,"acquired":false,"shares":30059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."}],"balance_after":30060,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30059},"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582399,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"exercise","planned":false,"acquired":false,"shares":20001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024."}],"balance_after":40003,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":20001},"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582398,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"exercise","planned":false,"acquired":false,"shares":14420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":14420},"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582397,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":14534,"price":25.79,"value":374831.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Reflects an aggregate of 14,534 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Reflects the closing price of ANIK common stock on March 11, 2024, the trading day on which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":151694,"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582396,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"exercise","planned":false,"acquired":true,"shares":30059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F7","text":"Reflects the second vesting installment of RSUs granted on March 11, 2022."}],"balance_after":166228,"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582395,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":6473,"price":25.42,"value":164543.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Reflects an aggregate of 6,473 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":136169,"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582394,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"exercise","planned":false,"acquired":true,"shares":20001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reflects the first vesting installment of RSUs granted on March 9, 2023."}],"balance_after":142642,"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582393,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":6973,"price":25.42,"value":177253.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects an aggregate of 6,973 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the closing price of ANIK common stock on March 8, 2024, the trading day prior to which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":122641,"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1582392,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:44.000Z","date":"2024-03-11","kind":"exercise","planned":false,"acquired":true,"shares":14420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 152 shares purchased on May 12, 2023 and 787 shares purchased on November 14, 2023."}],"balance_after":129614,"source":{"system":"sec-edgar","filing":"0001171843-24-001307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184324001307/ownership.xml","form_type":"4"}},{"id":1595234,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2024-03-05T22:57:53.000Z","date":"2024-03-01","kind":"grant","planned":false,"acquired":true,"shares":24761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2024."}],"balance_after":24761,"derivative":{"exercise_price":3.39,"expiration_date":"2034-03-01","underlying":"Common Stock","underlying_shares":24761},"source":{"system":"sec-edgar","filing":"0000950170-24-026413","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000095017024026413/ownership.xml","form_type":"4"}},{"id":1847703,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-22T01:48:21.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":40000,"derivative":{"exercise_price":0.96,"expiration_date":"2033-06-21","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001401914-23-000038","document":"wk-form4_1687398491.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191423000038/wk-form4_1687398491.xml","form_type":"4"}},{"id":1860366,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2023-06-09T20:10:20.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":13928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 7, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":13928,"derivative":{"exercise_price":10,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":13928},"source":{"system":"sec-edgar","filing":"0000899243-23-015166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000089924323015166/doc4.xml","form_type":"4"}},{"id":1911692,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2023-04-28T20:30:20.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":false,"shares":24575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":24575},"source":{"system":"sec-edgar","filing":"0001171843-23-002685","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323002685/ownership.xml","form_type":"4"}},{"id":1911691,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2023-04-28T20:30:20.000Z","date":"2023-04-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":10900,"price":26.34,"value":287106.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 10,900 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on April 26, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the closing price of ANIK common stock on April 26, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":114255,"source":{"system":"sec-edgar","filing":"0001171843-23-002685","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323002685/ownership.xml","form_type":"4"}},{"id":1911690,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2023-04-28T20:30:20.000Z","date":"2023-04-26","kind":"exercise","planned":false,"acquired":true,"shares":24575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the third and final vesting installment of Restricted Stock Units (RSUs) granted on April 26, 2020."}],"balance_after":125155,"source":{"system":"sec-edgar","filing":"0001171843-23-002685","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323002685/ownership.xml","form_type":"4"}},{"id":1955344,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2023-03-14T20:46:38.000Z","date":"2023-03-10","kind":"exercise","acquired":false,"shares":30060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."}],"balance_after":60119,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":30060},"source":{"system":"sec-edgar","filing":"0001171843-23-001684","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001684/ownership.xml","form_type":"4"}},{"id":1955343,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2023-03-14T20:46:38.000Z","date":"2023-03-10","kind":"tax_withholding","acquired":false,"shares":13211,"price":26.1,"value":344807.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects an aggregate of 13,211 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the closing price of ANIK common stock on March 10, 2023, the trading day immediately preceding the date on which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":100580,"source":{"system":"sec-edgar","filing":"0001171843-23-001684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001684/ownership.xml","form_type":"4"}},{"id":1955342,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2023-03-14T20:46:38.000Z","date":"2023-03-10","kind":"exercise","acquired":true,"shares":30060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 11, 2022."}],"balance_after":113791,"source":{"system":"sec-edgar","filing":"0001171843-23-001684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001684/ownership.xml","form_type":"4"}},{"id":1959615,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2023-03-10T21:51:15.000Z","date":"2023-03-09","kind":"exercise","acquired":false,"shares":14419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."}],"balance_after":14420,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":14419},"source":{"system":"sec-edgar","filing":"0001171843-23-001595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001595/ownership.xml","form_type":"4"}},{"id":1959614,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-10T21:51:15.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":130998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Represents a 10% premium above the closing price of Anika's common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The premium priced stock options vest in three equal annual installments beginning on March 9, 2024."}],"balance_after":130998,"derivative":{"exercise_price":29.6,"expiration_date":"2033-03-09","underlying":"Common Stock","underlying_shares":130998},"source":{"system":"sec-edgar","filing":"0001171843-23-001595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001595/ownership.xml","form_type":"4"}},{"id":1959613,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2023-03-10T21:51:15.000Z","date":"2023-03-09","kind":"grant","acquired":true,"shares":60004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2024."}],"balance_after":60004,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":60004},"source":{"system":"sec-edgar","filing":"0001171843-23-001595","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001595/ownership.xml","form_type":"4"}},{"id":1959612,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2023-03-10T21:51:15.000Z","date":"2023-03-09","kind":"tax_withholding","acquired":false,"shares":4232,"price":26.91,"value":113883.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects an aggregate of 4,232 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects the closing price of ANIK common stock on March 9, 2023, the trading day on which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":83731,"source":{"system":"sec-edgar","filing":"0001171843-23-001595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001595/ownership.xml","form_type":"4"}},{"id":1959611,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2023-03-10T21:51:15.000Z","date":"2023-03-09","kind":"exercise","acquired":true,"shares":14419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 540 shares purchased on May 13, 2022 and 178 shares purchased on November 14, 2022."}],"balance_after":87963,"source":{"system":"sec-edgar","filing":"0001171843-23-001595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184323001595/ownership.xml","form_type":"4"}},{"id":1972670,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2023-03-03T22:08:38.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":6432,"price":7.618,"value":48998.976,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2023."}],"balance_after":6432,"derivative":{"exercise_price":11.87,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":6432},"source":{"system":"sec-edgar","filing":"0000899243-23-007021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000089924323007021/doc4.xml","form_type":"4"}},{"id":2221923,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:18:55.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":38000,"derivative":{"exercise_price":1.31,"expiration_date":"2032-06-23","underlying":"Common stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001401914-22-000060","document":"wf-form4_165610191903120.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191422000060/wf-form4_165610191903120.xml","form_type":"4"}},{"id":2233924,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2022-06-13T20:05:51.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":12155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier to occur of (i) June 9, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":12155,"derivative":{"exercise_price":3.1,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":12155},"source":{"system":"sec-edgar","filing":"0000899243-22-022158","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000089924322022158/doc4.xml","form_type":"4"}},{"id":2289028,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2022-04-28T21:01:35.000Z","date":"2022-04-26","kind":"exercise","acquired":false,"shares":24576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."}],"balance_after":24575,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":24576},"source":{"system":"sec-edgar","filing":"0001171843-22-002980","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322002980/ownership.xml","form_type":"4"}},{"id":2289027,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2022-04-28T21:01:35.000Z","date":"2022-04-26","kind":"exercise","acquired":true,"shares":24576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the second vesting installment of Restricted Stock Units (RSUs) granted on April 26, 2020. The 24,576 shares resulting from the RSU vest were retained in full as a result of Dr. Blanchard's election to pay cash to cover the applicable taxes resulting from the RSU vest."}],"balance_after":72826,"source":{"system":"sec-edgar","filing":"0001171843-22-002980","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322002980/ownership.xml","form_type":"4"}},{"id":2334264,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-15T21:00:54.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":208821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a 10% premium above the closing price of Anika's common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The premium priced stock options vest in three equal annual installments beginning on March 11, 2023."}],"balance_after":208821,"derivative":{"exercise_price":28.14,"expiration_date":"2032-03-11","underlying":"Common Stock","underlying_shares":208821},"source":{"system":"sec-edgar","filing":"0001171843-22-001903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001903/ownership.xml","form_type":"4"}},{"id":2334263,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2022-03-15T21:00:54.000Z","date":"2022-03-11","kind":"grant","acquired":true,"shares":90179,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023."}],"balance_after":90179,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":90179},"source":{"system":"sec-edgar","filing":"0001171843-22-001903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001903/ownership.xml","form_type":"4"}},{"id":2336384,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2022-03-14T13:01:34.000Z","date":"2022-03-11","kind":"purchase","acquired":true,"shares":3813,"price":25.814,"value":98428.782,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 11, 2022, Dr. Blanchard purchased 3,813 shares in multiple trades ranging from $25.70 to $25.94. The price reported above reflects the weighted average purchase price. Dr. Blanchard undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001171843-22-001833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001833/ownership.xml","form_type":"4"}},{"id":2336383,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2022-03-14T13:01:34.000Z","date":"2022-03-11","kind":"purchase","acquired":true,"shares":4287,"price":25.359,"value":108714.033,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 11, 2022, Dr. Blanchard purchased 4,287 shares in multiple trades ranging from $24.69 to $25.69. The price reported above reflects the weighted average purchase price. Dr. Blanchard undertakes to provide the Securities and Exchange Commission staff, the issuer, or any security holder, upon request, full information regarding the number of shares and prices at which the transactions were effected."}],"balance_after":56179,"source":{"system":"sec-edgar","filing":"0001171843-22-001833","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001833/ownership.xml","form_type":"4"}},{"id":2338428,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2022-03-11T22:35:28.000Z","date":"2022-03-09","kind":"exercise","acquired":false,"shares":14420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."}],"balance_after":28839,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":14420},"source":{"system":"sec-edgar","filing":"0001171843-22-001809","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001809/ownership.xml","form_type":"4"}},{"id":2338427,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2022-03-11T22:35:28.000Z","date":"2022-03-09","kind":"exercise","acquired":true,"shares":14420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 9, 2021. The 14,420 shares resulting from the RSU vest were retained in full as a result of Dr. Blanchard's election to pay cash to cover the applicable taxes resulting from the RSU vest."}],"balance_after":51892,"source":{"system":"sec-edgar","filing":"0001171843-22-001809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184322001809/ownership.xml","form_type":"4"}},{"id":2353696,"issuer":{"id":11675,"kind":"organization","name":"Vigil Neuroscience, Inc.","symbol":"VIGL"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option Grant (Right to Buy)","published_at":"2022-03-03T21:05:37.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":5017,"price":9.63,"value":48313.71,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022."}],"balance_after":5017,"derivative":{"exercise_price":16.13,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":5017},"source":{"system":"sec-edgar","filing":"0000899243-22-009053","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000089924322009053/doc4.xml","form_type":"4"}},{"id":2655733,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-24T20:43:53.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":30000,"derivative":{"exercise_price":1.46,"expiration_date":"2031-06-24","underlying":"Common stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001401914-21-000094","document":"wf-form4_162456741352719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191421000094/wf-form4_162456741352719.xml","form_type":"4"}},{"id":2664899,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T20:31:11.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":2994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in three equal annual installments beginning on April 26, 2021."}],"balance_after":101644,"derivative":{"exercise_price":33.4,"expiration_date":"2030-04-26","underlying":"Common Stock","underlying_shares":2994},"source":{"system":"sec-edgar","filing":"0001171843-21-004397","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321004397/ownership.xml","form_type":"4"}},{"id":2664898,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2021-06-17T20:31:11.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":2994,"price":33.4,"value":99999.6,"ownership":{"direct":true},"balance_after":37472,"source":{"system":"sec-edgar","filing":"0001171843-21-004397","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321004397/ownership.xml","form_type":"4"}},{"id":2737698,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2021-04-28T21:00:33.000Z","date":"2021-04-26","kind":"exercise","acquired":false,"shares":24575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."}],"balance_after":49151,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":24575},"source":{"system":"sec-edgar","filing":"0001171843-21-002890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321002890/ownership.xml","form_type":"4"}},{"id":2737697,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2021-04-28T21:00:33.000Z","date":"2021-04-26","kind":"exercise","acquired":true,"shares":24575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects the first vesting installment of RSUs granted on April 26, 2020. The 24,575 shares resulting from the RSU vest were retained in full as a result of Dr. Blanchard's election to pay cash to cover the applicable taxes resulting from the RSU vest."}],"balance_after":34478,"source":{"system":"sec-edgar","filing":"0001171843-21-002890","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321002890/ownership.xml","form_type":"4"}},{"id":2795527,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-11T22:08:12.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":108398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a 10% premium above the closing price of Anika's common stock on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The premium priced stock options vest in three equal annual installments beginning on March 9, 2022."}],"balance_after":108398,"derivative":{"exercise_price":37.4,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":108398},"source":{"system":"sec-edgar","filing":"0001171843-21-001708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321001708/ownership.xml","form_type":"4"}},{"id":2795526,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2021-03-11T22:08:12.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":43259,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022."}],"balance_after":43259,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":43259},"source":{"system":"sec-edgar","filing":"0001171843-21-001708","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184321001708/ownership.xml","form_type":"4"}},{"id":3098397,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-27T00:56:38.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer."}],"balance_after":22500,"derivative":{"exercise_price":1.03,"expiration_date":"2030-06-25","underlying":"Common stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001401914-20-000097","document":"wf-form4_159321937668046.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191420000097/wf-form4_159321937668046.xml","form_type":"4"}},{"id":3132003,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-28T20:21:24.000Z","date":"2020-05-26","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock"}],"balance_after":34437,"source":{"system":"sec-edgar","filing":"0001192482-20-000403","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000119248220000403/edgar.xml","form_type":"4"}},{"id":3168607,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-28T22:41:06.000Z","date":"2020-04-26","kind":"grant","acquired":true,"shares":104638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock options vest in three equal annual installments beginning April 26, 2021."}],"balance_after":104638,"derivative":{"exercise_price":33.4,"expiration_date":"2030-04-26","underlying":"Common Stock","underlying_shares":104638},"source":{"system":"sec-edgar","filing":"0001171843-20-002971","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320002971/ownership.xml","form_type":"4"}},{"id":3168606,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Restricted Stock Unit","published_at":"2020-04-28T22:41:06.000Z","date":"2020-04-26","kind":"grant","acquired":true,"shares":73726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning April 26, 2021."}],"balance_after":73726,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":73726},"source":{"system":"sec-edgar","filing":"0001171843-20-002971","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320002971/ownership.xml","form_type":"4"}},{"id":3168605,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2020-04-28T22:41:06.000Z","date":"2020-04-26","kind":"tax_withholding","acquired":false,"shares":1794,"price":33.4,"value":59919.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Reflects an aggregate of 1,794 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on April 26, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects the closing price of the ANIK common stock on April 26, 2020, the trading day on which the vesting of RSUs gave rise to tax withholding obligations."}],"balance_after":9903,"source":{"system":"sec-edgar","filing":"0001171843-20-002971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320002971/ownership.xml","form_type":"4"}},{"id":3168604,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO, Director"}}],"security":"Common Stock","published_at":"2020-04-28T22:41:06.000Z","date":"2020-04-26","kind":"exercise","acquired":true,"shares":4231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects the vesting of RSUs granted on February 25, 2020 in accordance with the terms of Dr. Blanchard's agreement with the Company related to her appointment as its interim Chief Executive Officer."}],"balance_after":11697,"source":{"system":"sec-edgar","filing":"0001171843-20-002971","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320002971/ownership.xml","form_type":"4"}},{"id":3244742,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-02-27T23:48:27.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":4231,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). \"Term\" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The units shall vest in full and settle as of the earlier of (i) immediately prior to the end of the Term, so long as the Term does not end as the result of Dr. Blanchard's election to terminate her employment, and (ii) February 25, 2021, so long as Dr. Blanchard continues to serve on the Company's Board of Directors as of such date. Dr. Blanchard was recently appointed as the Company's interim Chief Executive Officer (CEO). \"Term\" is defined as Dr. Blanchard's employment as the Company's interim CEO ending on the earliest of (a) the effective date of the appointment by the Company of a permanent CEO, (b) August 7, 2020, (c) a Change in Control as defined in the Company's 2017 Omnibus Incentive Plan, and (d) such date as of which either the Company or Dr. Blanchard elect to terminate her employment as interim CEO."}],"balance_after":4231,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":4231},"source":{"system":"sec-edgar","filing":"0001171843-20-001357","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184320001357/ownership.xml","form_type":"4"}},{"id":3362886,"issuer":{"id":7799,"kind":"organization","name":"Dare Bioscience, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-11-22T00:55:16.000Z","date":"2019-11-20","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 1/3rd of the shares subject to this option on each of the first three anniversaries of the transaction date, subject to the reporting person's continued service to the issuer, and will become exercisable in full upon a change of control of the issuer."}],"balance_after":45000,"derivative":{"exercise_price":0.79,"expiration_date":"2029-11-20","underlying":"Common stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001401914-19-000100","document":"wf-form4_157438410017998.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191419000100/wf-form4_157438410017998.xml","form_type":"4"}},{"id":3507460,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-30T20:47:10.000Z","date":"2019-05-28","kind":"grant","acquired":true,"shares":7347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date."}],"balance_after":7347,"derivative":{"exercise_price":13.43,"expiration_date":"2029-05-27","underlying":"Common Stock","underlying_shares":7347},"source":{"system":"sec-edgar","filing":"0001209191-19-033450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000120919119033450/doc4.xml","form_type":"4"}},{"id":3507459,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-30T20:47:10.000Z","date":"2019-05-28","kind":"grant","acquired":true,"shares":3723,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award that vests on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":4437,"source":{"system":"sec-edgar","filing":"0001209191-19-033450","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000120919119033450/doc4.xml","form_type":"4"}},{"id":3627453,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-28T21:31:01.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":3842,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest in full on February 26, 2020."}],"balance_after":7466,"source":{"system":"sec-edgar","filing":"0001171843-19-001383","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184319001383/ownership.xml","form_type":"4"}},{"id":3653548,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-15T21:19:13.000Z","date":"2019-02-13","kind":"grant","acquired":true,"shares":1453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock options will vest on the earlier of the first anniversary of the date of grant and the date of the Issuer's next annual meeting of stockholders, subject to the the Reporting Person's continued service."}],"balance_after":1453,"derivative":{"exercise_price":17.45,"expiration_date":"2029-02-13","underlying":"Common Stock","underlying_shares":1453},"source":{"system":"sec-edgar","filing":"0001192482-19-000087","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000119248219000087/edgar.xml","form_type":"4"}},{"id":3653547,"issuer":{"id":6248,"kind":"organization","name":"Neuronetics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-15T21:19:13.000Z","date":"2019-02-13","kind":"grant","acquired":true,"shares":714,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Granted in the form of restricted stock units. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units will vest on the earlier of the first anniversary of the date of grant and the date of the Issuer's next annual meeting of stockholders, subject to the the Reporting Person's continued service."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Granted in the form of restricted stock units. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock."}],"balance_after":714,"source":{"system":"sec-edgar","filing":"0001192482-19-000087","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000119248219000087/edgar.xml","form_type":"4"}},{"id":3826124,"issuer":{"id":6005,"kind":"organization","name":"Anika Therapeutics, Inc."},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-09-05T20:15:29.000Z","date":"2018-08-31","kind":"grant","acquired":true,"shares":3624,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Anika Therapeutics, Inc. common stock. The restricted stock units vest immediately prior to the Anika Therapeutics, Inc. 2019 Annual Meeting of Stockholders."}],"balance_after":3624,"source":{"system":"sec-edgar","filing":"0001171843-18-006411","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898437/000117184318006411/ownership.xml","form_type":"4"}},{"id":3912293,"issuer":{"id":120832,"kind":"organization","name":"SeaSpine Holdings Corp","symbol":"SPNE"},"owners":[{"id":52260,"kind":"person","name":"Blanchard Cheryl R","position":1,"cik":"0001326530","reported_name":"Blanchard Cheryl R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-31T20:54:16.000Z","date":"2018-05-30","kind":"grant","acquired":true,"shares":8857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock award vests in full on May 30, 2019, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation (\"SeaSpine\") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting."}],"balance_after":28948,"source":{"system":"sec-edgar","filing":"0001637761-18-000097","document":"wf-form4_152779999647939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326530/000163776118000097/wf-form4_152779999647939.xml","form_type":"4"}}],"next_cursor":"2018-05-31T20:54:16.000000Z,3912293"}